Daré Bioscience reports Phase 1 data showing 187-fold lower peak plasma sildenafil with 3.6% topical cream vs oral dose
Bitget2026/10/08 13:15Daré Bioscience disclosed Phase 1 results for a topical sildenafil cream, with data set for presentation Oct. 9, 2026 at SMSNA. Study showed the cream produced much lower systemic drug exposure than oral sildenafil, supporting a localized delivery approach. Safety readout was clean, with only mild treatment-emergent adverse events reported and no serious events or discontinuations. Results underpin plans to advance the program toward an FDA 505(b)(2) filing as a potential treatment for female sexual arousal disorder. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080915PRIMZONEFULLFEED9842153) on October 08, 2026, and is solely responsible for the information contained therein.
- Daré Bioscience disclosed Phase 1 results for a topical sildenafil cream, with data set for presentation Oct. 9, 2026 at SMSNA.
- Study showed the cream produced much lower systemic drug exposure than oral sildenafil, supporting a localized delivery approach.
- Safety readout was clean, with only mild treatment-emergent adverse events reported and no serious events or discontinuations.
- Results underpin plans to advance the program toward an FDA 505(b)(2) filing as a potential treatment for female sexual arousal disorder.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
